Were Analysts Bullish Bristol-Myers Squibb Company (NYSE:BMY) This Week?

May 16, 2018 - By Jason Grubb

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.94 in 2017 Q4. Its down 0.09, from 1.03 in 2017Q3. It worsened, as 72 investors sold Bristol-Myers Squibb Company shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported.
Saratoga & Mgmt reported 0.02% in Bristol-Myers Squibb Company (NYSE:BMY). Agf Investments America reported 0.64% in Bristol-Myers Squibb Company (NYSE:BMY). Park National Oh holds 46,303 shares. Fincl Engines Advsr Ltd Liability owns 17 shares. Spears Abacus Advisors Llc reported 0.15% in Bristol-Myers Squibb Company (NYSE:BMY). 62,632 are owned by Brinker. Nadler Fincl Group has invested 0.12% in Bristol-Myers Squibb Company (NYSE:BMY). Pineno Levin And Ford Asset Management Inc reported 3,952 shares. Davenport And Limited Liability Com holds 0.87% in Bristol-Myers Squibb Company (NYSE:BMY) or 1.19 million shares. The Alabama-based Fjarde Ap has invested 0.43% in Bristol-Myers Squibb Company (NYSE:BMY). Maple Mngmt reported 0.11% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Farmers Co reported 10,426 shares. Blair William And Com Il invested in 763,477 shares. The Virginia-based Wilbanks Smith & Thomas Asset Management Ltd Llc has invested 0.43% in Bristol-Myers Squibb Company (NYSE:BMY). 408,602 are held by Gamco Et Al.

Since December 12, 2017, it had 2 insider buys, and 1 sale for $163,963 activity. 4,770 shares valued at $249,948 were bought by Paliwal Dinesh C on Monday, April 30. 4,000 Bristol-Myers Squibb Company (NYSE:BMY) shares with value of $249,187 were bought by Samuels Theodore R. II.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 11 analysts covering Bristol Myers (NYSE:BMY), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Bristol Myers has $78.0 highest and $47 lowest target. $65.56’s average target is 25.35% above currents $52.3 stock price. Bristol Myers had 17 analyst reports since February 6, 2018 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Friday, February 16. The firm has “Underperform” rating given on Wednesday, April 18 by BMO Capital Markets. Leerink Swann maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, February 6. Leerink Swann has “Buy” rating and $76.0 target. Morgan Stanley downgraded Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday, April 17 to “Equal-Weight” rating. As per Monday, March 5, the company rating was maintained by Bank of America. The rating was maintained by Jefferies on Monday, February 26 with “Hold”. BMO Capital Markets upgraded the shares of BMY in report on Friday, April 27 to “Market Perform” rating. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Friday, March 23 by Jefferies. Guggenheim maintained the shares of BMY in report on Tuesday, April 17 with “Buy” rating. The firm earned “Hold” rating on Wednesday, February 28 by DZ Bank. Below is a list of Bristol-Myers Squibb Company (NYSE:BMY) latest ratings and price target changes.

26/04/2018 Broker: Barclays Capital Rating: Hold New Target: $55.0000
27/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Market Perform Old Target: $47 Upgrade
20/04/2018 Broker: Cowen & Co Rating: Hold New Target: $60.0000 Maintain
18/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $51 New Target: $47 Maintain
17/04/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $68 New Target: $61 Maintain
17/04/2018 Broker: Guggenheim Rating: Buy New Target: $72.0000 Maintain
17/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade
13/04/2018 Broker: Jefferies Rating: Hold New Target: $66.0000 Maintain
23/03/2018 Broker: Jefferies Rating: Hold New Target: $70.0000 Maintain
20/03/2018 Broker: J.P. Morgan Rating: Buy New Target: $75.0

The stock increased 0.54% or $0.28 during the last trading session, reaching $52.3. About 8.13 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 16, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $85.51 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 85.74 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” on May 16, 2018, also Bizjournals.com with their article: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” published on May 01, 2018, Seekingalpha.com published: “Ziopharm, Trump’s Drug Pricing Plan And The Future Of Expensive Drug Development” on May 15, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” published on May 16, 2018 as well as Fool.com‘s news article titled: “Why Bristol-Myers Squibb Stock Crashed in April” with publication date: May 09, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.